Hanall Biopharma Stock Falls 6.87% After Partner Discontinues CLE Drug Trial
Hanall Biopharma's stock fell 6.87% to 43,400 won on the previous trading day following news that partner company Immunovant discontinued development of the cutaneous lupus erythematosus (CLE) indication for autoimmune disease drug candidate IMVT-1402 (imeloprubart). Immunovant announced on
HanAll Biopharma-0.36%
IMVT1.01%
GateMacroTradfiHub·09-28 21:40
